Cargando…

Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

Transarterial chemoembolization (TACE) is the standard treatment for patients with Barcelona Clinic Liver Cancer-intermediate stage hepatocellular carcinoma (HCC). The concept of drug-eluting bead TACE builds on the rationale of intratumoral drug delivery, and drug-eluting bead TACE has been shown t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Ji Hye, Lee, Jin-Woo, Hong, Ji Taek, Jin, Young-Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918291/ https://www.ncbi.nlm.nih.gov/pubmed/27508201 http://dx.doi.org/10.2147/JHC.S44380

Ejemplares similares

Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis
por: Jun, Baek Gyu, et al.
Publicado: (2018)

Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
por: Zhong, Bin-Yan, et al.
Publicado: (2023)

Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma
por: Nouri, Yasir M., et al.
Publicado: (2019)

Duodenal perforation and esophageal ischemia following transarterial chemoembolization for hepatocellular carcinoma: A case report
por: Kim, Shin Il, et al.
Publicado: (2016)

Ruptured Massive Hepatocellular Carcinoma Cured by Transarterial Chemoembolization
por: Lee, Ji Eun, et al.
Publicado: (2020)

Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis
por: Choi, Byung Ock, et al.
Publicado: (2008)

Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma
por: Nam, Hee Chul, et al.
Publicado: (2016)

Predictive Value of Procalcitonin for Bacterial Infection after Transarterial Chemoembolization or Radiofrequency Ablation for Hepatocellular Carcinoma
por: Kang, Seung Ji, et al.
Publicado: (2018)

Beneficial effects of Cripto-1 for transarterial chemoembolization in hepatocellular carcinoma
por: Li, Xiao-shan, et al.
Publicado: (2019)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

Radiomic advances in the transarterial chemoembolization related therapy for hepatocellular carcinoma
por: Chen, Tian-You, et al.
Publicado: (2023)

Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Vardar, Baran U, et al.
Publicado: (2022)

Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy
por: Zhang, Lei, et al.
Publicado: (2020)

Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
por: Jeon, Mi Young, et al.
Publicado: (2019)

Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma
por: Song, Myeong Jun, et al.
Publicado: (2016)

Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma
por: Park, Kil Hyo, et al.
Publicado: (2015)

Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Sohn, Won, et al.
Publicado: (2020)

Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Jeong, Shin Ok, et al.
Publicado: (2017)

Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
por: Baur, Johannes, et al.
Publicado: (2016)

Spinal Cord Infarction After Transarterial Chemoembolization for Hepatocellular Carcinoma
por: Lee, Sang-Geun, et al.
Publicado: (2022)

Multivariate Analysis of the Predictors of Survival for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Focusing on Superselective Chemoembolization
por: Ji, Suk Kyeong, et al.
Publicado: (2008)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Transarterial Chemoembolization in Combination with Local Therapies for Hepatocellular Carcinoma: A Meta-Analysis
por: Liao, Mingheng, et al.
Publicado: (2013)

Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma
por: Fukushima, Taito, et al.
Publicado: (2021)

Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
por: Adel, Hatem, et al.
Publicado: (2023)

The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
por: Shin, Sung Wook
Publicado: (2009)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
por: Fateen, Waleed, et al.
Publicado: (2017)

Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review
por: Sacco, Rodolfo, et al.
Publicado: (2017)

Transarterial chemoembolization for hepatocellular carcinoma in Fontan surgery patient
por: Orlacchio, Antonio, et al.
Publicado: (2020)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
por: Kotsifa, Evgenia, et al.
Publicado: (2022)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Liver abscess caused by Clostridium haemolyticum infection after transarterial chemoembolization for hepatocellular carcinoma: A case report
por: Son, Dong-Jun, et al.
Publicado: (2018)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients
por: Jung, Woo Jin, et al.
Publicado: (2022)

Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future
por: Woo, Hyun Young, et al.
Publicado: (2015)

Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery
por: Lim, Ji Young, et al.
Publicado: (2020)

Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
por: Song, Jeong Eun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_87car2c7ekkf579tvkak93ff7i